Green Thumb Industries (GTBIF) Liabilities and Shareholders Equity (2019 - 2026)
Green Thumb Industries' (GTBIF) quarterly Liabilities and Shareholders Equity came in at $2.8 billion in Q1 2026, up 10.22% YoY from $2.6 billion in Q1 2025, and up 1.49% on a QoQ basis from $2.8 billion in Q4 2025.
Green Thumb Industries (GTBIF) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $2.8 billion in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 10.22% year-over-year to $2.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 billion (up 6.37% YoY) and the FY2025 annual result came in at $2.8 billion, up 9.97% from the prior year.
- Liabilities and Shareholders Equity grew to $2.8 billion in Q1 2026, from $2.8 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.8 billion in Q1 2026 to a low of $2.4 billion in Q1 2022.
- A 5-year average of $2.5 billion and a median of $2.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 54.74% — and 2025, when it increased 0.3%.
- Tracing GTBIF's Liabilities and Shareholders Equity over 5 years: stood at $2.4 billion in 2022, then increased by 2.32% to $2.5 billion in 2023, then increased by 1.89% to $2.5 billion in 2024, then grew by 9.97% to $2.8 billion in 2025, then advanced by 1.49% to $2.8 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $2.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Green Thumb Industries | 1.69 Bn | 1.41 Bn | 137.87 Mn | 2.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.82 Bn |
| Mar 31, 2026 | 2.83 Bn |
| Dec 31, 2025 | 2.79 Bn |
| Sep 30, 2025 | 2.64 Bn |
| Jun 30, 2025 | 2.55 Bn |
| Mar 31, 2025 | 2.57 Bn |
| Dec 31, 2024 | 2.54 Bn |
| Sep 30, 2024 | 2.51 Bn |
| Jun 30, 2024 | 2.54 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 2.49 Bn |
| Sep 30, 2023 | 2.50 Bn |
| Jun 30, 2023 | 2.51 Bn |
| Mar 31, 2023 | 2.49 Bn |
| Dec 31, 2022 | 2.43 Bn |
| Sep 30, 2022 | 2.46 Bn |
| Jun 30, 2022 | 2.44 Bn |
| Mar 31, 2022 | 2.40 Bn |
| Dec 31, 2021 | 2.39 Bn |
| Sep 30, 2021 | 2.15 Bn |